Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

Published:2012-09 Issue:5 Volume:13 Page:391-395
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Scagliotti Giorgio V.,Novello Silvia,Schiller Joan H.,Hirsh Vera,Sequist Lecia V.,Soria Jean-Charles,von Pawel Joachim,Schwartz Brian,Von Roemeling Reinhard,Sandler Alan B.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

2. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

3. Treatment of non-small-cell lung cancer with erlotinib or gefitinib;Cataldo;N Engl J Med,2011

4. Expression and mutational analysis of MET in human solid cancers;Ma;Genes Chromosomes Cancer,2008

5. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer;Okuda;Cancer Sci,2008

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproducibility of c-Met Immunohistochemical Scoring (Clone SP44) for Non–Small Cell Lung Cancer Using Conventional Light Microscopy and Whole Slide Imaging;American Journal of Surgical Pathology;2024-07-08

2. Clinical significance of MET alterations in non-small cell lung cancer and currently available therapies;Malignant tumours;2023-11-08

3. MET alterations in advanced non-small cell lung cancer;Lung Cancer;2023-04

4. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision;Cancer Treatment Reviews;2022-11

5. Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis;Cancers;2022-07-11